Novel oral anticoagulants in development show indications toward reduced drug interactions, reduced interpatient pharmacokinetic variation, and similar morbidity and mortality benefits to current agents.
Novel oral anticoagulants in development may offer more predictable pharmacokinetics and fewer drug interactions compared to traditional anticoagulants, potentially improving clinical use and safety.
Chronic anticoagulation represents a clinical conundrum for the health care community that balances unquestionable morbidity and mortality benefits against interindividual variability, leading to drug interactions, adverse events, and thromoembolic events related to underdosing. Despite the growing data regarding the appropriate use and dosing of agents used for chronic anticoagulation, use in clinical practice remains low, thus leading to a theoretical reduction in the risk-to-benefit ratio in the clinical setting relative to that reported in the literature. Oral anticoagulants currently in development represent a heterogeneous group of compounds that are specific for the final common pathway in the coagulation cascade and show indications toward a reduced drug interaction profile, reduced interpatient variation in pharmacokinetic parameters, and morbidity and mortality benefits that might be similar to currently available treatment modalities. This review highlights the critical differences among oral anticoagulants in development and places their role in the context of the benefits and limitations of currently available anticoagulants.
Brian F. McBride (Fri,) conducted a review in Chronic anticoagulation. Novel oral anticoagulants in development vs. Currently available anticoagulants was evaluated. Novel oral anticoagulants in development show indications toward reduced drug interactions, reduced interpatient pharmacokinetic variation, and similar morbidity and mortality benefits to current agents.